NYSEMKT: CVMCel Sci Corp Stock
$1.01+0.00 (+0%)
Updated Oct 11, 2024
CVM Price
$1.01
Fair Value Price
N/A
Market Cap
$62.11M
52 Week Low
$1.00
52 Week High
$3.23
P/E
-1.74x
P/B
7.33x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$29.10M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.84
Operating Cash Flow
-$19M
Beta
0.86
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CVM Overview
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CVM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CVM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CVM is poor value based on its book value relative to its share price (7.33x), compared to the US Biotechnology industry average (6.1x)
P/B vs Industry Valuation
CVM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CVM due diligence checks available for Premium users.
Be the first to know about important CVM news, forecast changes, insider trades & much more!
CVM News
Valuation
CVM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.74x
Industry
-121.69x
Market
27.31x
CVM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.33x
Industry
6.1x
CVM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CVM's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.5M
Profit Margin
0%
CVM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$24.1M
Liabilities
$15.6M
Debt to equity
1.84
CVM's short-term liabilities ($5.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CVM's long-term liabilities ($10.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CVM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CVM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.6M
Investing
-$23.5k
Financing
-$322.3k
CVM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CVM vs Biotech Stocks
Cel Sci Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.